Markets:

Overview

News

Currencies

International

Treasuries

Enveric Biosciences, Inc. - Common Stock (NQ:ENVB)

4.095 +0.055 (+1.36%)

Streaming Delayed Price Updated: 1:40 PM EST, Jan 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Enveric Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Wednesday's session: gap up and gap down stocks ↗

September 17, 2025

Let's delve into the US markets on Wednesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

Via Chartmill

Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds

September 17, 2025

From Enveric Biosciences, Inc.

Via Business Wire

Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neuropsychiatric Drug Discovery

September 17, 2025

From Enveric Biosciences

Via Business Wire

Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission

September 16, 2025

From Enveric Biosciences

Via Business Wire

Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference

September 03, 2025

From Enveric Biosciences

Via Business Wire

Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA

September 02, 2025

From Enveric Biosciences

Via Business Wire

Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications

August 28, 2025

From Enveric Biosciences, Inc.

Via Business Wire

Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results

August 14, 2025

From Enveric Biosciences

Via Business Wire

Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

July 23, 2025

From Enveric Biosciences

Via Business Wire

Enveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD)

July 15, 2025

From Enveric Biosciences

Via Business Wire

Enveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003

June 24, 2025

From Enveric Biosciences

Via Business Wire

Enveric Biosciences Announces Participation in 2025 BIO International Convention

June 16, 2025

From Enveric Biosciences

Via Business Wire

Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders

June 10, 2025

From Enveric Biosciences

Via Business Wire

Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds

June 03, 2025

From Enveric Biosciences

Via Business Wire

Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003

May 28, 2025

From Enveric Biosciences

Via Business Wire

Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease

May 20, 2025

From Enveric Biosciences

Via Business Wire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

May 16, 2025

Via Benzinga

Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results

May 14, 2025

From Enveric Biosciences

Via Business Wire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

April 21, 2025

Via Benzinga

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024

March 31, 2025

From Enveric Biosciences

Via Business Wire

Enveric Biosciences Participating in BIO-Europe Spring®

March 17, 2025

From Enveric Biosciences, Inc.

Via Business Wire

Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark

March 06, 2025

From Enveric Biosciences

Via Business Wire

Keep an eye on the top gainers and losers in Friday's session. ↗

February 28, 2025

Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements.

Via Chartmill

These stocks have an unusual volume in today's session ↗

February 28, 2025

Volume analysis on 2025-02-28: stocks with an unusual volume in today's session.

Via Chartmill

Enveric Biosciences CEO Issues Letter to Shareholders

February 27, 2025

From Enveric Biosciences

Via Business Wire

These stocks are moving in today's after hours session ↗

February 26, 2025

Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session.

Via Chartmill

What's going on in today's session ↗

February 26, 2025

Wondering how the US markets performed one hour before the close of the markets on Wednesday? Discover the movers and shakers of today's session in our comprehensive analysis.

Via Chartmill

Check out the stocks that are attracting the most attention and driving market activity. ↗

February 26, 2025

Let's dive into the action on the US markets on Wednesday. Here are the most active stocks that are driving the market today.

Via Chartmill

Dow Dips Over 100 Points; TJX Earnings Top Views ↗

February 26, 2025

Via Benzinga

Topics Stocks

Here are the top movers in Wednesday's session. ↗

February 26, 2025

Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.